Please check your internet connection and try again.
# Septra (Co-trimoxazole)
## Overview
Co-trimoxazole is a combination antibiotic agent consisting of trimethoprim and sulfamethoxazole in a fixed ratio of 1:5. It is a broad-spectrum antibiotic effective against many gram-positive and gram-negative bacteria.
## Primary Indications
* Urinary tract infections (UTIs)
* Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
* Bacterial respiratory tract infections (e.g., acute exacerbations of chronic bronchitis)
* Shigellosis
* Traveler's diarrhea
* Certain types of pneumonia
## Adult Dosing
Dosing varies significantly based on indication. The ratio of trimethoprim:sulfamethoxazole is typically 1:5. For oral formulations, common strengths are 80 mg trimethoprim/400 mg sulfamethoxazole per tablet.
* **Urinary Tract Infections (Uncomplicated):** 1 double-strength (DS) tablet (160 mg trimethoprim/800 mg sulfamethoxazole) twice daily for 3-7 days.
* **Pneumocystis jirovecii Pneumonia (Treatment):** 15-20 mg/kg trimethoprim component per day, divided into 3-4 doses, for 14-21 days. Maximum daily dose often limited to 4 DS tablets.
* **Pneumocystis jirovecii Pneumonia (Prophylaxis):** 1 DS tablet (160 mg trimethoprim/800 mg sulfamethoxazole) daily, or 1 DS tablet three times weekly.
* **Other Infections:** Dosing is highly variable depending on the specific infection and severity, typically ranging from 800 mg to 1600 mg of sulfamethoxazole (equivalent to 1-2 DS tablets) every 12 hours.
## Pediatric Dosing
Dosing is based on the trimethoprim component and patient weight.
* **Urinary Tract Infections and Shigellosis:** 8 mg/kg of trimethoprim component per day, divided into two doses. For oral suspension, typically 40 mg/200 mg per 5 mL.
* **Pneumocystis jirovecii Pneumonia (Treatment):** 15-20 mg/kg of trimethoprim component per day, divided into 3-4 doses, for 14-21 days.
* **Pneumocystis jirovecii Pneumonia (Prophylaxis):** 5 mg/kg of trimethoprim component per day, divided into two doses, for 3 days a week, or 10 mg/kg per day divided into two doses, given 3 times a week.
## Dose Adjustments
* **Renal Impairment:** Dose adjustment is necessary based on creatinine clearance (CrCl).
* CrCl > 30 mL/min: No adjustment needed.
* CrCl 15-30 mL/min: Administer 75% of standard dose.
* CrCl < 15 mL/min: Avoid use or administer 50% of standard dose at 12-hour intervals.
* **Hepatic Impairment:** Use with caution; no specific dose adjustment guidelines are universally established, but monitor liver function closely.
## Contraindications
* Known hypersensitivity to trimethoprim, sulfamethoxazole, or sulfonamides.
* Infants less than 2 months of age (risk of kernicterus).
* Documented megaloblastic anemia due to folate deficiency.
* Severe renal or hepatic insufficiency.
* History of drug-induced immune thrombocytopenia with previous use of trimethoprim or sulfonamides.
## Adverse Effects
Common adverse effects include rash, pruritus, nausea, vomiting, and diarrhea. Serious adverse effects include:
* **Hematologic:** Agranulocytosis, aplastic anemia, thrombocytopenia, megaloblastic anemia (especially with prolonged use or in folate-deficient patients).
* **Dermatologic:** Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
* **Hepatic:** Hepatitis, cholestatic jaundice.
* **Renal:** Crystalluria, interstitial nephritis.
* **Electrolyte disturbances:** Hyperkalemia.
## Key Drug Interactions
* **Warfarin:** Increased INR; requires close INR monitoring and potential warfarin dose adjustment.
* **Methotrexate:** Increased risk of methotrexate toxicity; monitor methotrexate levels and blood counts. Co-administration with leucovorin rescue may be necessary.
* **Potassium-sparing diuretics (e.g., spironolactone, amiloride):** Increased risk of hyperkalemia.
* **ACE inhibitors/ARBs:** Increased risk of hyperkalemia.
* **Digoxin:** Increased digoxin levels, especially in patients with renal impairment.
* **Cyclosporine:** Increased cyclosporine levels, potentially leading to nephrotoxicity.
* **Oral contraceptives:** May decrease efficacy.
* **Potassium supplements:** Increased risk of hyperkalemia.
## Monitoring
* **Renal function:** Monitor serum creatinine and electrolytes, especially in patients with pre-existing renal disease or those receiving other nephrotoxic agents.
* **Complete blood counts (CBC):** Monitor for hematologic abnormalities, particularly with prolonged therapy or in at-risk individuals. Consider baseline and periodic monitoring.
* **Liver function tests:** Monitor if signs of hepatic dysfunction arise.
* **Potassium levels:** Monitor for hyperkalemia, especially in patients with renal impairment or taking other medications that affect potassium.
* **Skin:** Educate patients to report any rash or signs of hypersensitivity immediately.
## Clinical Pearls
* Encourage adequate fluid intake to prevent crystalluria.
* Co-trimoxazole can interfere with urine glucose testing, potentially causing false-positive or false-negative results depending on the method used.
* Sulfonamides can displace bilirubin from albumin, increasing the risk of kernicterus in jaundiced newborns.
* Be aware of potential cross-reactivity with other sulfonamide-containing drugs.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete and up-to-date details before making clinical decisions.*
